4D Molecular Therapeutics, Inc. reported positive 2-year data from the PRISM Phase 2b clinical trial evaluating 4D-150 for wet age-related macular degeneration. The trial results showed a 78% overall treatment burden reduction in the overall cohort and an 87% reduction in a recently diagnosed subgroup. 4D Molecular Therapeutics, Inc. is a biotechnology company that develops therapeutic solutions for ocular diseases.
